Eye Health Academy

Improving Clinical
Decision Making with
Engaging CME, Tools,
& Resources

SLT as First-Line Therapy
SLT as First-Line Therapy
Glaucoma
SLT as First-Line Therapy
Beyond IOP: Integrating Ocular Surface Resilience Into Glaucoma Management
Beyond IOP: Integrating Ocular Surface Resilience Into Glaucoma Management
CME/CE
Beyond IOP: Integrating Ocular Surface Resilience Into Glaucoma Management
1.00 credit
- Walter O. Whitley, OD, FAAO
- Nate Lighthizer, OD, FAAO, FAAOMS
- Jessica Steen, OD, FAAO, Dipl-ABO
1.00 credit
Hidden in Plain Sight: A Modern Guide to Detecting and Managing Early Neurotrophic Keratitis
Hidden in Plain Sight: A Modern Guide to Detecting and Managing Early Neurotrophic Keratitis
CME/CE
Hidden in Plain Sight: A Modern Guide to Detecting and Managing Early Neurotrophic Keratitis
1.00 credit
- Cecelia Koetting, OD, FAAO
- Lisa Hornick, OD, MBA, FAAO
- Katherine Rachon, OD, FAAO
1.00 credit
Racial/Ethnic Disparities in TDR, DME, and Other Vision Threats in Patients With DR
Racial/Ethnic Disparities in TDR, DME, and Other Vision Threats in Patients With DR
Ophthalmology
Racial/Ethnic Disparities in TDR, DME, and Other Vision Threats in Patients With DR
- Jordan Deaner
- Vaidehi S. Dedania, MD
- Rehan M. Hussain, MD
Trends in PDR Treatments
Trends in PDR Treatments
Ophthalmology
Trends in PDR Treatments
- Maria H. Berrocal, MD
- Katharine Talcott, MD
Logistical Considerations with Anti-VEGF Treatment in Wet AMD
Logistical Considerations with Anti-VEGF Treatment in Wet AMD
Eye on Ocular Health
Logistical Considerations with Anti-VEGF Treatment in Wet AMD
CME/CE In-Person Event
International Congress of Scleral Contacts (ICSC) 2026
June 05, 2026
San Diego, California
MH Risk Factors After RRD Repair
MH Risk Factors After RRD Repair
Ophthalmology
MH Risk Factors After RRD Repair
- Maria H. Berrocal, MD
- Avni P. Finn, MD, MBA

Clinical Practice

GLP-1 Use and AMD Risk
GLP-1 Use and AMD Risk
Ophthalmology
GLP-1 Use and AMD Risk
- Barton Lynn Blackorby, MD
- Katharine Talcott, MD
- Hong-Uyen Hua, MD
Distinguishing Urgent vs. Monitorable Retinal Vein Occlusion
Distinguishing Urgent vs. Monitorable Retinal Vein Occlusion
Eye on Ocular Health
Distinguishing Urgent vs. Monitorable Retinal Vein Occlusion
- Ashkan Abbey, MD
Time to Recurrence and Early Risk Indicators in BRVO-Related Macular Edema
Time to Recurrence and Early Risk Indicators in BRVO-Related Macular Edema
Eye on Ocular Health
Time to Recurrence and Early Risk Indicators in BRVO-Related Macular Edema
Examining Therapeutic Timing in RVO-Related Macular Edema
Examining Therapeutic Timing in RVO-Related Macular Edema
Eye on Ocular Health
Examining Therapeutic Timing in RVO-Related Macular Edema
Real-World Switching to Faricimab from Legacy Anti-VEGFs in Wet AMD
Real-World Switching to Faricimab from Legacy Anti-VEGFs in Wet AMD
Ophthalmology
Real-World Switching to Faricimab from Legacy Anti-VEGFs in Wet AMD
- Maria H. Berrocal, MD
- Lejla Vajzovic, MD, FASRS
How Anti-VEGF Compares with Steroids in Retinal Vein Occlusion
How Anti-VEGF Compares with Steroids in Retinal Vein Occlusion
Eye on Ocular Health
How Anti-VEGF Compares with Steroids in Retinal Vein Occlusion
- Ryan Quigley
It Takes a Village, Part of the Focused Sight Initiative: Quality Improvement Interventions in Retinal Disease
It Takes a Village, Part of the Focused Sight Initiative: Quality Improvement Interventions in Retinal Disease
CME/CE
It Takes a Village, Part of the Focused Sight Initiative: Quality Improvement Interventions in Retinal Disease
0.25 credits
- David Eichenbaum, MD
0.25 credits
Suprachoroidal Steroids in Patients With a History of Glaucoma and Ocular Hypertension
Suprachoroidal Steroids in Patients With a History of Glaucoma and Ocular Hypertension
Ophthalmology
Suprachoroidal Steroids in Patients With a History of Glaucoma and Ocular Hypertension
- Maria H. Berrocal, MD
- Danny Mammo, MD

Popular

Clinical Practice

Title

Share on ReachMD